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Abstract
Background: The association between impaired lung function and diabetes risk has been established in the past,
however the temporal and causal relationships between the two remain unclear. We assessed the relationship
between baseline FEV1 and FVC and risk of incident diabetes at different time intervals for participants in the
Malmö Preventive Project cohort.
Methods: Baseline lung function was assessed in 20,295 men and 7416 women during 1974–1992; mean
age 43.4 ± 6.6 and 47.6 ± 7.8, respectively. Sex-specific quartiles of FEV1%predicted and FVC%predicted were
created (Q4 = highest; reference). Follow-up time was divided into 10-year time intervals from baseline examination.
Cox proportional hazards regression was used to assess the incidence of diabetes according to quartiles of FEV1 and
FVC%predicted, after adjustments for baseline glucose and potential confounding factors.
Results: Over 37-years’ follow-up there were 3753 and 993 incident diabetes events in men and women, respectively.
When comparing FEV1%predicted in men (Q1 vs. Q4), the HR for diabetes was 1.64 (1.21–2.22) for events <10 years
after baseline, 1.52 (1.27–1.81) for events 10–20 years after baseline, 1.39 (1.22–1.59) for events 20–30 years after
baseline, and 1.46 (1.08–1.97) for events occurring >30 years after baseline. A broadly similar pattern was seen for
FVC%predicted and for women.
Conclusions: Low FEV1 precedes and significantly predicts future diabetes. This risk is still significant many years
after the baseline FEV1 measurement in middle-aged men. These results suggest that there is a relationship
between impaired lung function and diabetes risk beyond the effects of hyperglycemia on lung function.
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Background
Poor lung function has been long found to have a rela-
tionship with important health outcomes beyond the
effect of smoking [1]. One of these important relation-
ships is the complex interaction between diabetes and
lung function. Although cross-sectional studies have
found that patients with diabetes tend to have poorer
lung function than non-diabetics [2–6], the temporality
of a causal relationship has remained controversial in
longitudinal studies. Some longitudinal studies have
explored the relationship between diabetes and lung
function decline later in life and found an association
[3, 7], whereas others have not [5, 8]. The proposed
mechanisms have included microangiopathy of lung
vasculature, chronic inflammation, autonomic neuropathy
involving the lung, and loss of elastic recoil due to glyco-
sylation of lung parenchyma, i.e. adverse effects of high
glucose levels [9]. However, more recently poor lung func-
tion has been thought to be a potential novel risk marker
for future diabetes and there have been a number of longi-
tudinal studies that have explored poor lung function at
baseline and the future risk of diabetes [10–18]. The
relationship between impaired lung function and diabetes
is important to explore as further understanding of this
relationship can help inform strategies to impact the
burden of significant conditions related to both poor
lung function and diabetes, such as cardiovascular dis-
ease (CVD). Stratifying a long-term prospective analysis
into different follow-up periods can help further under-
stand the temporal relationship between diabetes and
lung function.
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We have previously used the Malmö Preventive Pro-
ject (MPP) cohort to report that subjects with a moder-
ately reduced forced vital capacity (FVC) at baseline run
an increased risk of developing insulin resistance and
diabetes after 14-years of follow-up [11]. The aim of the
present longitudinal cohort study is to add clarity to the
temporal relationship between poor lung function and
diabetes in a prospective study from the general popula-
tion. We aim to do this by firstly establishing if poor
lung function (as defined by low %predicted forced
expiratory volume in one second (FEV1) or FVC) is a
predictor of future diabetes and secondly if so, how
long time-wise from the baseline lung function meas-
urement this risk can be observed. As systemic inflam-
mation is often thought to be a common factor that
links both poor lung function and diabetes, we also aim




The study population for the present study is derived
from the MPP. A total of 33,346 subjects (22,444 men
and 10,902 women) participated in screening activities
between 1974 and 1992 (attendance rate over 70 %),
with an aim to screen a large population of middle-aged
individuals and offer preventive treatment to any high
risk individuals identified during screening. Complete
birth cohorts, born between 1921 and 1949, were invited
for health screening which included a physical examin-
ation, a panel of laboratory tests, spirometry and a self-
administered questionnaire.
The Health Service Authority of Malmö approved the
screening program, and linkage with the national cause
of death and patient registers was approved by the
Regional ethics committee at Lund University. Men
were mostly screened during 1974–82 and women were
mostly screened during 1982–92. From the total study
population those with a history of diabetes at baseline
(prevalent diabetes) were excluded (n = 1173). Spirom-
etry was performed in birth cohorts during most but
not all screening time periods (94 % of men and 71 %
of women underwent spirometry) however individuals
were not selected based on symptoms or disease. Those
with missing FVC or FEV1 were then excluded (n =
4149) from the study. Individuals with missing informa-
tion on baseline glucose (n = 120), height (n = 1), BMI
(n = 2), erythrocyte sedimentation rate (ESR) (n = 58),
smoking status (n = 5), cholesterol (n = 38), or informa-
tion on family history of diabetes (n = 31) were also
excluded. We also excluded individuals with an ESR
≥50 mm/h as this may indicate any specific inflamma-
tory lung pathology (n = 58). The final study population
thus consisted of 27,711 subjects (20,295 men and 7416
women).
Since diabetes develops gradually and can go undetected
for a long time, we performed a subgroup analysis of indi-
viduals who were confirmed to be non-diabetic at least
10 years after the baseline screening. Between 1992 and
1994, the cardiovascular cohort of the Malmö Diet and
Cancer study (MDC-CC) was performed, which included
measurements of fasting blood glucose [19]. Of the 27,711
subjects in the present study, 2539 men and women
participated also in the MDC-CC. Of them, 1530 individ-
uals were examined at least 10-years after the initial
screening in the MPP cohort and were non-diabetic when
they were re-examined in the MDC study (i.e. fasting
blood glucose <6.1 mmol/L, no self-reported diabetes or
anti-diabetic medication). Figure 1 illustrates the flow of
subjects through the study.
Baseline examinations
FEV1 and FVC were measured using a Spirotron appar-
atus (Drägerwerk AG, Lübeck, Germany) carried out by
trained nursing staff. One acceptable manoeuvre was
required. FEV1 and FVC were standardised for age and
height using published equations derived from linear
regression of never-smokers in the present cohort [20–22].
The equations used for computing predicted values
were as follows:
Men:
Predicted FEV1 Lð Þ: 4:422 height mð Þ − 0:0381
age yearsð Þ − 2:483
Predicted FVC Lð Þ: 6:58 height−0:033 age−5:54
Women:
Predicted FEV1 Lð Þ: 3:615 height−0:0217
age−2:134
Predicted FVC Lð Þ: 4:866 height−0:020
age−3:644
FEV1 and FVC were then expressed as a percentage of
the predicted values (FEV1%predicted and FVC%pre-
dicted). Sex-specific quartiles of FEV1%predicted and
FVC%predicted were then constructed. In addition, we
also tested the relationships with incidence of diabetes
using published European prediction equations [23] in a
sensitivity analysis.
Height (m) was measured using a fixed stadiometer;
weight (kg) was measured using a balance beam scale.
Blood samples were taken after an overnight fast and
analysed using routine methods at the Department of
Clinical Chemistry, Malmö University Hospital. ESR
was determined according to the Westergren method.
Information on smoking habits, alcohol use and use
of anti-hypertensive medication or family history of
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diabetes was assessed in a questionnaire. Based on their
responses to smoking habit questions, subjects were
classified as never, former or current smokers. Alcohol
abuse was assessed using a panel of nine questions
related to alcohol use where >2 positive responses was
considered problematic alcohol use [24]. In men, phys-
ical activity was assessed using a question “Are you
mostly engaged in sedentary activity in your spare
time?” Some questions were changed during the screen-
ing period. In women, physical activity was therefore
assessed using the questions, “Are you engaged in phys-
ical activity (e.g., swimming, gymnastics, badminton,
tennis, folk dance, running, etc.) 1–2 hours per week?”
or “Do you usually get to do light physical exercise like
walking or cycling (or other activities with similar effort)
on a regularly weekly basis?”. Low socioeconomic status
was defined as Statistics Sweden socioeconomic index
(SEI) group 11–36 (i.e. unskilled or skilled manual
workers or low-level non-manual workers).
Information about inflammatory markers was available in
a subgroup of 5133 men. Complement 3 (C3), fibrinogen,
ceruloplasmin, haptoglobin, orosomucoid and alpha-1 anti-
trypsin were analysed using electroimmunoassay. This sub-
group has been described in detail elsewhere [25, 26].
Endpoint ascertainment
Prevalent diabetes was defined as a fasting whole blood
glucose ≥6.1 mmol/L at baseline (corresponding to a
plasma glucose ≥7.0 mmol/L), self-reported diabetes or
diabetes medication according to the questionnaire, or
any prior diagnosis of diabetes in the registers used for
follow-up (see below). Individuals with prevalent dia-
betes (n = 1173) were excluded from all analyses. All
subjects were followed from the baseline examination
until first diabetes event, death, emigration, or last
follow-up date (31st December 2012), whichever came
first. Incident diabetes was defined using the Malmö
HbA1c Register (MHR), the Swedish National Diabetes
Fig. 1 Illustrates the flow of subjects from MPP cohort and MDC-CC cohort
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Register (NDR), the Swedish Hospital Discharge Register,
the Swedish Outpatient Register, the nationwide Swedish
Drug Prescription register and the regional Diabetes
2000 Register of the Scania region. Incident cases of
diabetes were also retrieved from re-examinations of
individuals in the MPP cohort [19, 27]. The MHR
register includes all glycated haemoglobin (HbA1c)
values collected from individuals in institutional and
non-institutional care in the greater Malmö area from
1988 onwards. HbA1c was analysed at the Department
of Clinical Chemistry, Malmö University Hospital.
The Swedish Hospital discharge register has been op-
erating in the south of Sweden since 1970 and
became nationwide in 1987. The Swedish Drug Pre-
scription register has been operating since 2005. NDR
and the Diabetes 2000 Register required a physician
diagnosis according to established diagnostic criteria
(fasting plasma glucose concentration of ≥7.0 mmol/L
measured on two different occasions). Individuals
with at least two HbA1c values ≥6.0 % according to the
Swedish Mono-S standardization system (corresponding
to 7.0 % with the US National Glycohemoglobin
Standardization Program) recorded in the MHR after the
baseline examination were defined as having incident dia-
betes mellitus (DM).
Statistical analysis
All statistical analyses were carried out using SPSS ver-
sion 22.0 and STATA V.12.0. To assess the relationship
between baseline lung function and incident diabetes
according to different follow-up times, the follow-up
period was divided into four time intervals: 0–10 years,
10–20 years, 20–30 years and >30 years. Only the first
diabetes events were counted, i.e. an individual could
only be a diabetes case in one of the four time periods.
The follow-up time was limited to the maximum time
for each time interval. For example, for the 10–20 years
interval, all participants with a follow-up time >10 years
were included but only diabetes events with first diagno-
sis between 10 and 20 years were included in the ana-
lysis and any follow-up time over 20 years was limited to
20 years only. Sex-specific quartiles of FEV1%predicted
and FVC%predicted were created (1 = low lung function
and 4 = reference). Variables with a positively skewed
distribution were log-transformed (ESR). One way ana-
lysis of variance (ANOVA) and Pearson’s chi-square test
were used to compare baseline characteristics between
subjects in quartiles of FEV1%predicted and FVC%pre-
dicted. Cox proportional hazards regression was used to
assess incidence of diabetes according to different quar-
tiles of lung function with and without adjustment for
potential confounding factors. Cox proportional hazards
assumption was tested visually using Kaplan Meier plots
and log-log plots for the overall follow-up time. Fine and
Gray’s proportional sub-hazards model was used to carry
out competing risks regression to correct for the effect
of deaths from causes unrelated to diabetes. Sub-hazard
ratios for incident diabetes with deaths (with no diabetes
diagnosis) as a competing event was obtained (adjusted
for potential confounding factors).
Results
Subject characteristics are presented in Tables 1 and 2.
Those with poorer lung function reported a higher
smoking prevalence in both men and women. Those in
Q1 of FEV1%predicted had slightly higher BMI than
those in Q4, and tended to be more physically inactive,
have higher alcohol consumption and more likely to be
on blood pressure (BP) medication. ESR and cholesterol
levels were higher in Q1 vs. Q4 (p <0.001). Similar
findings were seen for FVC%predicted (see Additional
file 1: Table S1a and S1b).
Incidence of diabetes
Mean follow-up was 27 years for men and 26 years for
women. During full follow-up, there were 3753 and 993
incident diabetes events in men and women, respect-
ively. The mean FEV1%predicted values for those who
developed diabetes during follow-up and those who did
not were 93.0 and 95.9 % respectively in men, and 92.6
and 95.8 % respectively in women. The corresponding
values for FVC%predicted were 94.9 and 97.6 % respect-
ively in men, and 94.8 and 97.6 % respectively in women.
Hazard ratios (HR) of incident diabetes by quartiles of
lung function are shown in Tables 3 and 4. For the over-
all follow-up time there was an approximately 40–50 %
increase in adjusted risk of diabetes in Q1 of FEV1%pre-
dicted and FVC%predicted relative to Q4; for both males
and females (see Additional file 1: Table S2a and S2b for
FVC%predicted).
HR for diabetes per 10 % decrease in FEV1%predicted
for the overall follow-up time were 1.09 (CI: 1.07–1.11)
in men, and 1.07 (CI: 1.03–1.11) in women. HR for
diabetes per 10 % decrease in FVC%predicted were 1.10
(CI: 1.08–1.13) and 1.07 (CI: 1.03–1.11) in men and
women, respectively.
We compared these results to those obtained from
using European prediction equations for FEV1 and FVC
[23] (see Additional file 1: Tables S3 and S4) and found
the results to be very similar to the results from our
own MPP cohort prediction equations.
The adjusted sub-hazards ratio, taking into account
deaths from other causes before a diabetes diagnosis
occurred, remained significant in Q1 and Q2 of both
FEV1%predicted and FVC%predicted in men and women
for the overall follow-up period (see Additional file 1:
Table S5).
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Table 2 Baseline characteristics in relation to quartiles of FEV1%predicted: Females (n = 7416)
Overall Q4 Q3 Q2 Q1 P value for trend
FEV1%predicted 95.4 (±18.1) 116.9 (±10.2) 101.3 (±3.0) 90.9 (±3.2) 72.5 (±11.9) –
Number (n) 7416 1854 1854 1854 1854 –
Age (years) 47.6 (±7.8) 48.0 (±6.6) 46.9 (±7.8) 46.6 (±8.6) 48.8 (±8.1) 0.023
Height (m) 1.64 (±0.06) 1.64 (±0.06) 1.64 (±0.06) 1.64 (±0.06) 1.64 (±0.06) 0.868
Current-smokers (%) 45.2 27.0 38.8 48.4 66.6 <0.001
BMI (kg/m2) 23.8 (±3.9) 23.8 (±3.5) 23.7 (±3.7) 23.7 (±3.9) 24.0 (±4.4) 0.135
Physical inactivity (%) 43.3 36.6 40.6 45.0 51.0 <0.001
- Missing data (%) 12.2 11.2 13.9 14.5 9.2
Anti-hypertensive medication (%) 6.6 5.0 6.5 6.3 8.6 <0.001
High alcohol consumption (%) 2.7 2.5 2.4 2.9 3.1 0.150
ESR (mm/h)a 7.47 6.99 7.13 7.48 8.36 <0.001
Baseline glucose (mmol/L) 4.74 (±0.52) 4.70 (±0.52) 4.74 (±0.51) 4.75 (±0.53) 4.79 (±0.53) <0.001
Cholesterol (mmol/L) 5.67 (±1.10) 5.64 (±1.07) 5.62 (±1.08) 5.62 (±1.11) 5.79 (±1.12) <0.001
Family history of diabetes (%) 16.0 16.0 16.1 15.2 16.7 0.788
Social class (%) 0.785
- Low skilled 44.9 42.2 43.8 45.0 48.5
- High skilled 45.4 48.5 48.2 45.4 39.5
- Self-employed 2.9 3.1 2.3 3.2 3.0
- Other 6.8 6.3 5.8 6.4 8.9
Q Quartile, FEV1 Forced expiratory volume 1 s, BMI body mass index, ESR Erythrocyte sedimentation rate. Data consist of mean (±standard deviation) unless
otherwise stated. aGeometric mean presented for ESR. Linear by linear association for chi square tests used for p value for categorical variables, ANOVA test for
linearity used for p value for continuous variables
Table 1 Baseline characteristics in relation to quartiles of FEV1%predicted: Males (n = 20,295)
Overall Q4 Q3 Q2 Q1 P value for trend
FEV1%predicted 95.4 (±17.7) 117.0 (±9.9) 100.7 (±3.1) 90.3 (±3.2) 73.3 (±11.3) –
Number (n) 20,295 5074 5074 5074 5073 –
Age (years) 43.4 (±6.6) 43.9 (±6.5) 42.9 (±6.6) 42.8 (±6.6) 44.0 (±6.7) 0.350
Height (m) 1.77 (±0.07) 1.77 (±0.07) 1.77 (±0.07) 1.77 (±0.07) 1.77 (±0.07) 0.820
Current-smokers (%) 49.1 35.8 43.4 53.5 63.8 <0.001
BMI (kg/m2) 24.6 (±3.2) 24.4 (±2.9) 24.5 (±3.1) 24.5 (±3.2) 24.8 (±3.6) <0.001
Physical inactivity (%) 52.4 45.9 50.4 54.6 58.6 <0.001
Anti-hypertensive medication (%) 3.7 3.0 3.5 3.5 4.7 <0.001
High alcohol consumption (%) 17.8 15.6 16.8 18.7 20.1 <0.001
ESR (mm/h)a 4.05 3.86 3.90 4.01 4.46 <0.001
Baseline glucose (mmol/L) 4.93 (±0.50) 4.89 (±0.49) 4.94 (±0.51) 4.94 (±0.50) 4.94 (±0.52) <0.001
Cholesterol (mmol/L) 5.59 (±1.05) 5.52 (±1.01) 5.56 (±1.03) 5.60 (±1.06) 5.66 (±1.08) <0.001
Family history of diabetes (%) 11.0 11.4 10.1 10.8 11.8 0.371
Social class (%) 0.125
- Low skilled 44.9 42.5 42.6 45.8 48.8
- High skilled 43.9 47.1 47.3 42.3 38.8
- Self-employed 8.3 8.0 8.0 9.0 8.0
- Other 3.0 2.5 2.5 2.9 4.5
Q Quartile, FEV1 Forced expiratory volume 1 s, BMI body mass index, ESR Erythrocyte sedimentation rate. Data consist of mean (±standard deviation) unless
otherwise stated. aGeometric mean presented for ESR. Linear by linear association for chi square tests used for p value for categorical variables, ANOVA test for
linearity used for p value for continuous variables
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To assess the effect of inflammatory factors on the
relationship between lung function and diabetes, a sub-
analysis was carried out on a smaller cohort of men with
information on ESR, white cell count (WCC), comple-
ment C3, fibrinogen, haptoglobin, ceruloplasmin, alpha-
1 antitrypsin and orosomucoid (Table 5). For the overall
follow-up period, HR (Q1 vs Q4) was 1.36 (CI: 1.14–
1.63) for FEV1%predicted after adjusting for risk factors.
The HR decreased slightly, but remained significant,
after further adjustment for inflammatory markers (1.29,
CI: 1.07–1.54, p for trend ≤0.001). HRs were slightly
lower for FVC%predicted but largely similar (see Additional
file 1: Table S6).
There was no significant interaction between smoking
status and FEV1%predicted (p = 0.49 for men and 0.11
for women) or FVC%predicted (p = 0.88 for men and
0.98 for women) over the entire follow-up time (see
Additional file 1: Table S7a-S7d for a stratified analysis
by smoking status).
To assess the relationship between an obstructive lung
pattern at baseline and future risk of diabetes we carried
out an analysis comparing those with FEV1/FVC <70 %
to those with FEV1/FVC ≥70 % (see Additional file 1:
Table S8). After adjustment the risk for diabetes did not
remain significant for both men and women with an
FEV1/FVC <70 % relative to those ≥70 %.
Since diabetes can go undetected for a long time, an
additional analysis was performed in a subgroup of 1530
men and women who were (a) re-screened with a meas-
urement of fasting blood glucose as part of the Malmö
diet and cancer (MDC-CC) study cohort and (b) still free
from diabetes after more than 10 years (mean 14.1 years,
range 10–18.4) from initial screening in the MPP study. A
total of 214 subjects developed diabetes after this re-
Table 3 Hazard ratios of diabetes mellitus by quartiles of FEV1%predicted in males: stratified by follow-up time (years) (n = 20,295)
follow-up time (years)
(n = number of incident DM events)
Q4 (reference) Q3 Q2 Q1 P value
for trend
≥106.34 95.57–106.34 84.65–95.57 ≤84.65
Overall follow-up time (n = 3753) Unadjusted risk 1.00 1.13 (1.02–1.24)* 1.26 (1.15–1.39)*** 1.77 (1.61–1.94)*** <0.001
Adjusted riska 1.00 1.06 (0.97–1.17) 1.15 (1.05–1.27)** 1.48 (1.35–1.63)*** <0.001
0–10 years (n = 365) Unadjusted risk 1.00 1.09 (0.78–1.54) 1.25 (0.90–1.74) 2.41 (1.80–3.23)*** <0.001
Adjusted riska 1.00 0.99 (0.70–1.38 1.06 (0.76–1.47) 1.64 (1.21–2.22)** <0.001
10–20 years (n = 1059) Unadjusted risk 1.00 1.05 (0.87–1.27) 1.25 (1.04–1.50)* 1.94 (1.64–2.30)*** <0.001
Adjusted riska 1.00 0.98 (0.81–1.19) 1.12 (0.93–1.35) 1.52 (1.27–1.81)*** <0.001
20–30 years (n = 1984) Unadjusted risk 1.00 1.18 (1.04–1.34)* 1.30 (1.15–1.48)*** 1.59 (1.40–1.81)*** <0.001
Adjusted risk*a 1.00 1.12 (0.98–1.27) 1.20 (1.05–1.36)** 1.39 (1.22–1.59)*** <0.001
>30 years (n = 345) Unadjusted risk 1.00 1.08 (0.80–1.46) 1.10 (0.81–1.50) 1.59 (1.18–2.13)** 0.004
Adjusted riska 1.00 1.06 (0.79–1.44) 1.06 (0.77–1.44) 1.46 (1.08–1.97)* 0.023
aAdjusted for: age, height, BMI, smoking status, ESR (log transformed), baseline glucose, cholesterol, physical activity, BP medication, social class, family history of
diabetes, and alcohol abuse. *p <0.05 **p < 0.01 ***p <0.001 P value for trend calculated using cox regression models (1 d.f)
Table 4 Hazard ratios of diabetes mellitus by quartiles of FEV1%predicted in females: stratified by follow-up time (years) (n = 7416)
follow-up time (years)
(n = number of incident DM events)
Q4 (reference) Q3 Q2 Q1 P value
for trend
≥106.67 96.13–106.67 85.14–96.12 ≤85.13
Overall follow-up time (n = 993) Unadjusted risk 1.00 1.34 (1.11–1.62)** 1.40 (1.16–1.70)*** 1.94 (1.62–2.33)*** <0.001
Adjusted riska 1.00 1.26 (1.04–1.53)* 1.26 (1.04–1.53)* 1.45 (1.20–1.75)*** <0.001
0–10 years (n = 135) Unadjusted risk 1.00 2.19 (1.23–3.89)** 2.09 (1.17–3.72)* 2.77 (1.59–4.83)*** 0.001
Adjusted riska 1.00 2.00 (1.12–3.58)* 1.72 (0.95–3.11) 1.68 (0.94–3.01) 0.275
10–20 years (n = 395) Unadjusted risk 1.00 1.38 (1.01–1.87)* 1.44 (1.06–1.95)* 2.00 (1.50–2.67)*** <0.001
Adjusted riska 1.00 1.33 (0.98–1.81) 1.37 (1.01–1.87)* 1.51 (1.11–2.05)** 0.012
20–30 years (n = 419) Unadjusted risk 1.00 1.13 (0.85–1.50) 1.33 (1.01–1.75)* 1.73 (1.32–2.28)*** <0.001
Adjusted riska 1.00 1.04 (0.78–1.39) 1.16 (0.87–1.54) 1.32 (0.99–1.76) 0.043
>30 years (n = 44) Unadjusted risk 1.00 1.49 (0.60–3.69) 0.73 (0.26–2.00) 1.91 (0.78–4.70) 0.355
Adjusted riska 1.00 1.58 (0.63–3.94) 0.79 (0.28–2.20) 2.35 (0.93–5.90) 0.186
aAdjusted for: age, height, BMI, smoking status, ESR (log transformed), baseline glucose, cholesterol, physical activity, BP medication, social class, family history of
diabetes, and alcohol abuse. *p <0.05 **p < 0.01 ***p < 0.001. P value for trend calculated using cox regression models (1 d.f)
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examination. In these subjects it was found that for every
10 % decrease in FEV1%predicted there was a 11 % in-
crease in adjusted risk of diabetes (HR 1.11 (CI: 1.02–
1.21)) and for every 10 % decrease in FVC%predicted
there was a 12 % increase in adjusted risk of diabetes (HR
1.12 (CI: 1.02–1.23)). The corresponding HRs were signifi-
cant also when standardised European reference values
were used to calculate predicted FEV1 and FVC (HR 1.13
(CI: 1.03–1.23), and 1.14 (CI: 1.04–1.25), respectively).
Incidence of diabetes by length of follow-up
When stratified into follow-up time intervals, low FEV1%-
predicted was found to be a significant risk factor for
diabetes in men even after >30 years of follow-up (Fig. 2).
The HR (Q4 vs. Q1) for diabetes was 1.64 (CI: 1.21–2.22)
for events <10 years after baseline, 1.52 (CI: 1.27–1.81) for
events 10–20 years after baseline, 1.39 (CI: 1.22–1.59) for
events 20–30 years after baseline, and 1.46 (CI: 1.08–1.97)
for events occurring >30 years after baseline. The rela-
tionships were largely similar for FVC%predicted (see
Additional file 1: Table S2a and S2b) and for women,
although confidence intervals were larger for women.
Discussion
The temporal and causal relationship between lung
function and diabetes has remained controversial in
longitudinal studies. Our study explores the temporal
relationship through stratified analyses based on follow-up
time. The main finding was that the risk of future diabetes
remains significant even after many years of follow-up
from baseline poor lung function.
Table 5 Hazard ratios of diabetes mellitus by quartiles of FEV1%predicted in males: sub-cohort further adjusted for inflammation
(5133 men)
follow-up time (years)
(n = number of incident DM events)
Q4 (reference) Q3 Q2 Q1 P value
for trend
≥106.39 95.20–106.39 83.51–95.17 ≤83.50
Follow-up time 0–37 years (n = 1025) Adjusted riska 1.00 0.94 (0.78–1.13) 1.24 (1.04–1.48)* 1.36 (1.14–1.63)** <0.001
Further adjusted for
inflammationb
1.00 0.91 (0.75–1.09) 1.20 (1.01–1.44)* 1.29 (1.07–1.54)** <0.001
aAdjusted for: age, height, BMI, smoking status, baseline glucose, cholesterol, physical activity, BP medication, social class, family history of diabetes, alcohol abuse
bFurther adjusted for ESR (log transformed), WCC, Fibrinogen, complement C3, haptoglobin, ceruloplasmin, alpha-1 antitrypsin, and orosomucoid. *p <0.05 **p < 0.01. P
value for trend calculated using cox regression models (1 d.f)
Fig. 2 Hazard ratios for Q1 FEV1%predicted and incident diabetes for various follow-up times in males and females
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In our study of 27,711 subjects followed over 36–37
years, FVC and FEV1 were found to be powerful predic-
tors of future diabetes, even following adjustment for
baseline glucose levels and BMI. The mean baseline lung
function was lower in those who then developed dia-
betes compared to those who did not. The differences
were smaller than that reported previously [28]. How-
ever, since we report results from a longitudinal follow-
up study of initially non-diabetic subjects, the results
may differ from cross-sectional studies comparing dia-
betic cases and controls. In both men and women there
was a high adjusted risk found even in non-smokers at
certain time intervals (which was also higher than that
of smokers during some time periods) confirming previ-
ous findings that the relationship of poor health out-
comes associated with poor lung function goes beyond
the effect of smoking [1, 29, 30]. As systemic inflamma-
tion has been thought to be a common cause of poor
lung function and diabetes, we assessed this link using
various inflammatory markers. Even following adjust-
ment for these markers in a smaller cohort of men, there
was still a 29 % increase in risk in Q1 of FEV1%pre-
dicted. Our study findings also show that an obstructive
lung phenotype at baseline (i.e. low FEV1/FVC) is not
associated with future diabetes risk (Additional file 1:
Table S8), whereas poor %predicted values of either
FEV1 or FVC continue to result in an increased diabetes
risk even after many years duration. These findings are
mirrored by other prospective studies where a reduc-
tion in FEV1 and FVC at baseline but not the ratio
of FEV1/FVC is associated with an increased risk of
diabetes [14, 17, 18].
There is a large body of studies that have assessed
poor lung function in relation to diabetes or prediabetes
risk [5, 10–18, 31–33]. There are substantial epidemio-
logical implications of this association, in particular the
possibility that diabetes and insulin resistance can ex-
plain the association between impaired lung function
and the high risk of CVD and mortality [1, 34]. Our
results have been in accordance with previous prospect-
ive studies that have assessed poor lung function and
future risk of diabetes [5, 11, 14] and expand the results
by exploring the increased risk over a long follow-up
period.
The proposed mechanisms for the relationships be-
tween impaired lung function and diabetes include, for
example, microangiopathy of lung vasculature, chronic
inflammation, autonomic neuropathy, and loss of elastic
recoil due to glycosylation of lung parenchyma, i.e.,
adverse effects of high glucose levels [9]. However, it
seems unlikely that hyperglycaemia had major effects on
lung function many years prior to the diagnosis of dia-
betes. Individuals with diabetes were excluded at base-
line and in addition all results were adjusted for glucose
at baseline. Our data suggest that there may exist a
causal relationship between FEV1 and diabetes risk be-
yond the effects of hyperglycemia on lung function.
It has been proposed the mechanism that may link poor
lung function to diabetes risk include reduced physical
activity often associated with poor lung function, which
predisposes to weight gain leading to the development of
metabolic syndrome [13, 35]. In our study, risks were
found to be significant even following adjustment for
physical activity as assessed by questions based on the
proportion of sedentary time in men and participation
in high and low intensity physical activities in women.
Chronic inflammation is also often thought to be a
common factor linking lung function and diabetes risk.
When adjusting for inflammatory factors in our study,
there was a small reduction in diabetes risk which still
remained significant for both Q1 of FEV1%predicted
and FVC%predicted suggesting that markers of inflam-
mation may not fully explain the underlying mechan-
ism linking lung function and diabetes.
The role of early life factors can also play a vital role
in the association between poor lung function and
diabetes. Foetal programming and detrimental early life
factors such as low birth weight can affect lung develop-
ment and the development of diabetes, as it has been
found that low birth weight is associated with poor adult
lung function [36] and the later development of type 2
diabetes [37]. This hypothesis has been tested in a study
by Yeh et al. [14] and it was found that although low
FVC%predicted was associated with low birth weight,
the association between FVC%predicted and incident
diabetes was mainly independent of low birth weight.
However further studies testing the role of foetal pro-
gramming beyond the role of birth weight may be neces-
sary, for example the influence of prematurity or maternal
smoking during pregnancy.
Common genetic determinants for diabetes and poor
lung function could be another possible explanation for the
increased incidence of diabetes. Several genetic markers
have been found to be associated with poor lung function
[38]. However, the effects of single nucleotide polymor-
phisms are usually weak and it is unlikely that these
markers explain more than a minor fraction of the relation-
ship between poor lung function and risk of diabetes.
Although this was beyond the scope of the present study, it
nevertheless could be an aspect of future observational
studies assessing the relationship between poor lung func-
tion and diabetes.
Limitations
There are some methodological issues that need to be
considered for this observational study. Firstly, the
protocol was developed before the current guidelines for
spirometry were developed. For example, no nose clips
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were used and only one acceptable manoeuvre of FEV1
and FVC was carried out. Although trained nursing staff
were used to carry out measurements, this could poten-
tially result in measurement errors. Due to the long
follow-up time there may be some characteristics that
may have changed during 36–37 years of follow-up such
as smoking status, BMI or the use of medications such
as statins and corticosteroids along with additional co-
morbidities. The prevalence of smoking in Sweden de-
creased over the duration of this study [39] and we can
assume that many smokers quit smoking during the
follow-up. However, non-smokers that start smoking in
adulthood are quite unusual [40], so we do not antici-
pate that the relationship between poor lung function
and diabetes was confounded by an increase in smoking
habits during the study. Statin treatment and the use of
oral corticosteroids may indeed increase the risk of
diabetes in some individuals, however where possible we
have tried to control for many of these effects by adjust-
ment for factors such cholesterol levels and BMI but
there may be some residual effect of changes in these
factors over time that could affect the outcome in some
subjects.
It is well known that type 2 diabetes can go undetected
for a long time and it is not possible to establish the
exact time of onset. The definition of diabetes has chan-
ged over time and before 1998, when the World Health
Organization (WHO) recommendations were published
[41], plasma glucose ≥7.8 mmol/L was commonly used
instead of the currently used cut-off of 7.0 mmol/L. This
would increase incidence of diabetes during the last time
periods. It is also possible that detection rates have
increased due to increased awareness of diabetes in the
health care organization. Also, the coverage of the regis-
ters used to identify new cases has improved over time,
i.e. the first diagnosis of diabetes in our registers may
not always represent the true onset of disease. However,
in a subgroup analysis we found that reduced lung func-
tion was associated with future diabetes risk even in
individuals whose blood glucose was normal more than
10 years (range 10–18 years) after the baseline examin-
ation. This strongly supports our conclusion that reduced
lung function remains predictive for incident diabetes
even after many years of follow-up.
Our findings were more statistically significant in men
for trends across quartiles of both FEV1 and FVC%pre-
dicted and the risk of incident diabetes. However this
can be due to statistical power as the population of
women studied was much smaller. The point estimates
were largely comparable in men and women.
We used various inflammatory markers to assess if a
significant relationship between lung function and dia-
betes risk remains after taking systemic inflammation into
account. Complement C3, WCC and fibrinogen have been
associated with increased risk of diabetes and low lung
function in previous studies [25, 26]. Although we in-
cluded a wide range of inflammatory markers in the
adjustment there may exist other important inflammatory
markers, such as interleukin-6 (IL-6) and C-reactive Pro-
tein (CRP) [18, 42, 43], that may be associated with poor
lung function and diabetes. Therefore the role of in-
flammation cannot be fully excluded. Obesity has been
thought to be an important factor in the relationship
between poor lung function and diabetes. We did not
adjust our findings for abdominal obesity using waist
circumference, therefore our measures of obesity corre-
sponds to over overall obesity alone. Both BMI and
waist circumference are major risk factors for type 2
diabetes and although waist circumference is a some-
what stronger predictor for type 2 diabetes compared
to BMI, prospective studies show that the effects of
these risk factors are largely comparable [44, 45].
Latent autoimmune diabetes in adults (LADA) is an
additional important subgroup of adult diabetic subjects
[46] and data on glutamic acid decarboxylase antibodies
was not available for most cases. Even though a large
majority of diabetes patients in this age group have Type
2 diabetes, and most cases with Type 1 diabetes were
excluded from the study as prevalent cases, some inci-
dent cases were patients with LADA.
Conclusion
Low FEV1 precedes and significantly predicts future
diabetes, and the relationship is not fully explained by
obesity, inflammation or smoking. This risk is still sig-
nificant many years after the baseline FEV1 measure-
ment in middle-aged men. These results suggest that
there is a relationship between impaired lung function
and diabetes risk beyond the specific effects of hyper-
glycemia on lung function. Further work is needed to
establish if early life factors or genetic factors affecting
both lung growth and impaired glucose metabolism
may be responsible.
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